Table 1.
Baseline characteristics of randomized controlled trials included in the meta-analysis.
| Study, year | No. enrolled | Mean age | Men, % | Hypertension, % | Diabetes, % | Mean LVEF,% | Mean left atrial diameter, mm | Statin type | Control group | Mean follow-up duration, months | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Almroth H, 2009 | 234 | 65 | 75 | 47 | 8.5 | NA | 44 | Atorvastatin 80 mg | Placebo | 6 | 5 |
| Ozaydin M, 2006 | 48 | 63 | 60 | 40 | 22.9 | 62 | 45 | Atorvastatin 10 mg | No statin treatment | 3 | 3 |
| Stop AF, 2011 | 64 | 58.5 | 82.9 | 50 | 8 | 48 | 46.1 | Atorvastatin 80 mg | Placebo | 12 | 4 |
| Tveit A, 2004 | 114 | 68 | 77 | 43 | 6.5 | NA | 44 | Pravastatin 40 mg | No statin treatment | 2 | 3 |
| Xia W, 2009 | 64 | 61.5 | 66 | 0 | 0 | 59 | 41.6 | Rosuvastatin 20 mg | No statin treatment | 3 | 2 |
LVEF – left ventricular ejection fraction; NA – not available.